Puma Biotech (PBYI) Tops Q4 EPS by 2c ; Offers Guidance

Puma Biotech (NASDAQ: PBYI) reported Q4 EPS of $0.29, $0.02 better than the analyst estimate of $0.27. Revenue for the quarter came in at $75.5 million versus the consensus estimate of $66.6 million.

GUIDANCE:

Puma Biotech sees Q1 2026 revenue of $38-42 million, versus the consensus of $49 million.

Puma Biotech sees FY2026 revenue of $214-221 million, versus the consensus of $220 million.

For earnings history and earnings-related data on Puma Biotech (PBYI) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Invesco Mortgage Capital declares $0.12 monthly dividend for June 2026
• Laser Photonics regains NASDAQ compliance after filing quarterly report